|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Swiss drugmaker Roche upped its bet on personalised cancer treatment on Monday, saying it is now ready to sell a blood test around the world that can identify common gene mutations from solid tumours from a patient's blood. The blood test, called FoundationOne Liquid, is among initial products to emerge from Foundation Medicine after Roche spent $2.4 billion on the U.S.-based genetic profiling company this year on the conviction that future cancer treatment will be tailored to individual characteristics of a patient's tumour.
Incyte (INCY) inks an agreement with Foundation Medicine for the development of companion diagnostics (CDx) for Incy's selective FGFR Inhibitor, pemigatinib.
Foundation Medicine, today announced the publication of the results of a large study demonstrating that its novel, investigational assay to measure blood tumor mutational burden (bTMB) can help predict response to the anti-PD-L1 immunotherapy, atezolizumab, (TECENTRIQ®) in patients with previously treated non-small cell lung cancer (NSCLC). The study, published in the journal Nature Medicine, was the result of a collaboration between Foundation Medicine and Genentech, a member of the Roche Group, and demonstrates the potential of bTMB to expand precision oncology approaches for patients with advanced cancers, including metastatic lung cancer. In addition, these results show that bTMB may be an independent predictor of clinical benefit, regardless of PD-L1 expression as assessed by immunohistochemistry.
OTCQX: RHHBY) and Foundation Medicine, Inc. (FMI) today announced that Roche`s wholly owned subsidiary 062018 Merger Subsidiary, Inc. has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of Foundation Medicine not already owned by Roche or its affiliates, at a price of $137.00 per share in cash. The tender offer expired at 12:00 midnight, Eastern Time, at the end of the day on 30 July 2018 and was not extended.
LONDON, UK / ACCESSWIRE / July 27, 2018 / If you want a free Stock Review on TROV sign up now at www.wallstequities.com/registration. WallStEquities.com draws investors' attention to the Medical Laboratories and Research category, which includes companies that focus on performing various tests on patients that give them information on patients' health. Lined up for review are the following equities: Foundation Medicine Inc. (NASDAQ: FMI), NeoGenomics Inc. (NASDAQ: NEO), Neuronetics Inc. (NASDAQ: STIM), and TrovaGene Inc. (NASDAQ: TROV).
Foundation Medicine, Inc. and Guardant Health, Inc. announced an agreement to settle a patent infringement lawsuit brought by Foundation Medicine against Guardant concerning U.S.
OTCQX: RHHBY) today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Foundation Medicine, Inc. (NASDAQ: FMI) at a price of US$ 137.00 per share. The tender offer is being made pursuant to the previously announced merger agreement dated as of 18 June 2018 among Foundation Medicine, Inc., Roche Holdings, Inc., an indirect wholly owned subsidiary of Roche Holding Ltd, and 062018 Merger Subsidiary, Inc., a wholly owned subsidiary of Roche Holdings, Inc. The tender offer period will expire at 12am midnight, Eastern Time, at the end of the day on 30 July 2018, unless the offer is extended.
Roche (RHHBY) will buy the remaining stake in Foundation Medicine for $2.4 billion. PTC Therapeutics (PTCT) presents encouraging preliminary data from an early-stage study in spinal muscular atrophy.
Foundation Medicine, Sarepta Therapeutics, and PTC Therapeutics reported market-moving news that every biotech investor ought to know about.
NEW YORK, NY / ACCESSWIRE / June 20, 2018 / Shares of Foundation Medicine exploded on Tuesday after announcing that it has entered into a definitive merger agreement for Roche to acquire the outstanding shares of FMI`s common stock not already owned by Roche and its affiliates at a price of US$ 137.00 per share. Shares of Solid Biosciences also broke out after announcing that the FDA has lifted a clinical hold on the company's phase I/II trial, IGNITE DMD, for its experimental candidate, SGT-001. Foundation Medicine, Inc. shares closed up 28.46% on Tuesday, with about 6.3 million shares traded compared to an average trading volume of about 409,00 shares.
Roche inks a deal with Foundation Medicine to acquire the remaining shares of Foundation Medicine, not already owned by it for a total consideration of $2.4 billion.